Use of amantadine in Parkinson's disease. Results of a double-blind trial
V Dallos, K Heathfield, P Stone, F A Allen, V Dallos, K Heathfield, P Stone, F A Allen
Abstract
In a four-week double-blind trial of 62 patients with Parkinsonism 29 were treated withamantadine and 33 with a placebo. Modest but statistically significant improvement was observed in the first group, optimum benefit occurring after the first two weeks. Patients' reactions to the drug were favourable in 79%, and side effects were insignificant. Though amantadine appears to be a useful additive drug in the treatment of Parkinsonism, its value as a single treatment is as yet undetermined.
References
- JAMA. 1969 May 19;208(7):1168-70
- Lancet. 1970 Feb 7;1(7641):259-62
- Lancet. 1970 Mar 7;1(7645):522
- Br Med J. 1970 Feb 21;1(5694):474-5
- Lancet. 1970 May 30;1(7657):1127-9
- Lancet. 1970 May 30;1(7657):1130-3
Source: PubMed